NCT06800157View on ClinicalTrials.gov

Study of LW402 Tablets in Moderate to Severe Rheumatoid Arthritis

PHASE2CompletedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

February 27, 2023

Primary Completion Date

May 26, 2024

Study Completion Date

August 30, 2024

Conditions
Arthritis, Rheumatoid
Interventions
DRUG

Drug: LW402

Oral tablets administered BID

DRUG

Other: placebo

Placebo to match LW402 administered BID

DRUG

MTX

Background treatment with MTX once a week

Trial Locations (1)

100730

Peking Union Medical College Hospital, Beijing

All Listed Sponsors
lead

Shanghai Longwood Biopharmaceuticals Co., Ltd.

INDUSTRY

NCT06800157 - Study of LW402 Tablets in Moderate to Severe Rheumatoid Arthritis | Biotech Hunter | Biotech Hunter